首页 | 本学科首页   官方微博 | 高级检索  
检索        


Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada,January 1, 1999 to June 30, 2001
Authors:Raymond SW Tsang  Susan G Squires  Wendell D Zollinger  Fraser E Ashton
Institution:1.CNS Infection Division, National Microbiology Laboratory, Winnipeg, Manitoba;2.Division of Respiratory Diseases, Bureau of Infectious Disease, Population and Public Health Branch, Health Canada, Ottawa, Ontario;3.Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, District of Columbia, USA
Abstract:The relative frequency of serogroups of Neisseria meningitidis associated with meningococcal disease in Canada during the period January 1, 1999 to June 30, 2001 was examined. Of the 552 strains of N meningitidis collected from clinical specimens of normally sterile sites, 191 (34.6%), 276 (50.0%), 61 (11.1%) and 23 (4.2%) were identified by serological and molecular methods as serogroups B, C, Y and W135, respectively. About half (50.8%) of the serogroup Y isolates were isolated in the province of Ontario. The two most common serotypes found were 2c and 14. Most of the serogroup Y strains isolated from patients in Ontario were serotype 2c, while serotype 14 was the most common serotype associated with disease in the province of Quebec. The two most common serosubtypes found among the serogroup Y meningococci were P1.5 and P1.2,5. Laboratory findings, based on antigenic analysis, did not suggest that these serogroup Y strains arise by capsule switching from serogroups B and C strains. This study documented a higher incidence of finding serogroup Y meningococci in clinical specimens from patients in Ontario compared to the rest of Canada, and parallels the increase in serogroup Y meningococcal disease reported in some parts of the United States.Key Words: Meningococcal disease, Neisseria meningitidis, SerogroupsInvasive meningococcal disease (IMD) is a notifiable communicable disease that is monitored by a national surveillance program coordinated by the Division of Disease Surveillance and the Division of Respiratory Diseases, Centre for Infectious Disease Prevention and Control, Health Canada. Starting in 1971 and with the help of provincial public health officials, Health Canada began to collect data on the serogroup information on IMD cases. Also, isolates of meningococci collected from patients are routinely sent to Health Canada''s National Microbiology Laboratory (NML) in Winnipeg for further antigenic and genetic analyses.IMD is a serious disease globally but the serogroups of meningococci causing diseases in various countries may vary in frequency. For example, serogroup A is a major cause of disease in Africa and China (1), while serogroups B and C meningococci are the most frequent cause of IMD in Western countries (2). In Canada, most IMD cases are caused by meningococci belonging to serogroups B, C, Y and W135. Serogroups B and C account for over 75% of the isolates collected from patients (3).In the past decade, Neisseria meningitidis serogroup Y has emerged as a frequent cause of IMD in the United States (4,5). In view of these findings, it is important to monitor the incidence of serogroup Y disease. This report presents the frequency of isolation of serogroups of meningococci in normally sterile clinical specimens collected from patients (likely to be presented as IMD) in various parts of Canada and describes the distribution of serotypes and serosubtypes found among the serogroup Y isolates.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号